[go: up one dir, main page]

WO2001088162A3 - Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations - Google Patents

Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations Download PDF

Info

Publication number
WO2001088162A3
WO2001088162A3 PCT/US2001/014817 US0114817W WO0188162A3 WO 2001088162 A3 WO2001088162 A3 WO 2001088162A3 US 0114817 W US0114817 W US 0114817W WO 0188162 A3 WO0188162 A3 WO 0188162A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
processes
relates
methods
avian species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/014817
Other languages
English (en)
Other versions
WO2001088162A2 (fr
Inventor
Lingxun Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenWay Biotech Inc
Original Assignee
GenWay Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/573,442 external-priority patent/US6951742B1/en
Application filed by GenWay Biotech Inc filed Critical GenWay Biotech Inc
Priority to AU2001259631A priority Critical patent/AU2001259631A1/en
Publication of WO2001088162A2 publication Critical patent/WO2001088162A2/fr
Publication of WO2001088162A3 publication Critical patent/WO2001088162A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Bioethics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de production d'anticorps polyclonaux et monoclonaux dirigés contre un antigène chez une espèce aviaire, de préférence chez un poulet, au moyen d'une vaccination polynucléotidique. L'invention concerne également des procédés de détermination du profil protéomique d'un ensemble de séquences d'ADN présélectionnées isolées d'un échantillon biologique, de préférence le profil protéomique d'une banque d'ADNc humains. L'invention concerne en outre des procédés d'identification de marqueurs physiologiquement différenciables associés à un échantillon biologique physiologiquement anormal. L'invention concerne finalement des réseaux d'anticorps, des bases de données intégrées destinées à l'identification de gènes et de protéines, des vecteurs d'expression de gènes multi-fonctionnels, ainsi que des procédés de production et d'utilisation de ces réseaux d'anticorps, des bases de données intégrées et des vecteurs d'expression de gènes multi-fonctionnels.
PCT/US2001/014817 2000-05-16 2001-05-07 Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations Ceased WO2001088162A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001259631A AU2001259631A1 (en) 2000-05-16 2001-05-07 Methods and vectors for generating antibodies in avian species and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20489900P 2000-05-16 2000-05-16
US09/573,442 US6951742B1 (en) 1998-11-16 2000-05-16 Methods and vectors for generating antibodies in avian species and uses therefor
US09/573,442 2000-05-16
US60/204,899 2000-05-16

Publications (2)

Publication Number Publication Date
WO2001088162A2 WO2001088162A2 (fr) 2001-11-22
WO2001088162A3 true WO2001088162A3 (fr) 2002-09-19

Family

ID=26899888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014817 Ceased WO2001088162A2 (fr) 2000-05-16 2001-05-07 Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations

Country Status (2)

Country Link
AU (1) AU2001259631A1 (fr)
WO (1) WO2001088162A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359913A1 (en) * 2001-12-20 2003-07-09 Agricultural Research Council Semi-synthetic antibody fragment combinatorial library based on avian immunoglobulin genes
CN1818651B (zh) * 2006-03-13 2010-07-21 东北农业大学 兔抗鹅IgY+IgY(△Fc)(H+L)辣根过氧化物酶标记抗体
KR20110058861A (ko) * 2008-08-29 2011-06-01 심포젠 에이/에스 조류 유래 항체의 클로닝 방법
CN107574157A (zh) 2009-03-16 2018-01-12 盘古生物制药有限公司 包含具有非经典生物活性的组氨酰‑tRNA合成酶剪接变异体的组合物及方法
CN102449143B (zh) 2009-03-31 2017-11-14 Atyr医药公司 包含具有非常规生物活性的天冬氨酰‑tRNA合成酶的组合物和方法
WO2011139714A2 (fr) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase
CA2797362C (fr) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques d'isoleucyl arnt synthetases
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797374C (fr) 2010-04-29 2021-02-16 Pangu Biopharma Limited Decouverte innovante de compositions therapeutiques, diagnostiques et a based' anticorps associees a des fragments proteiques d'asparaginyl-arnt-synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011140132A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011140267A2 (fr) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
CA2799197C (fr) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Decouverte de compositions inedites de nature therapeutique, diagnostique et a base d'anticorps contenant des fragments proteiques de phenylalanyl-beta-arnt synthetases
CA2799480C (fr) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic, et d'anticorps associees a des fragments proteiques de leucyl-arnt synthetases
EP2575856B1 (fr) 2010-05-27 2017-08-16 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
EP2575857B1 (fr) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques, et d'anticorps associés à des fragments de protéine de lysyl-tarn synthétases
CA2804416C (fr) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de glycyl-arnt synthetases
WO2012027611A2 (fr) 2010-08-25 2012-03-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et d'anticorps associées à des fragments protéiniques des tyrosyl-arnt synthétases
JP6039656B2 (ja) 2011-06-01 2016-12-07 メディカル プログノシス インスティテュート エー／エス 癌再発の予後予測のための方法および装置
EP2814514B1 (fr) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
JP6309019B2 (ja) 2012-11-27 2018-04-11 ポンティフィシア・ウニベルシダッド・カトリカ・デ・チレＰｏｎｔｉｆｉｃｉａ Ｕｎｉｖｅｒｓｉｄａｄ Ｃａｔｏｌｉｃａ ｄｅ Ｃｈｉｌｅ 甲状腺腫瘍を診断するための組成物および方法
WO2014195032A1 (fr) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Procédés et dispositifs pour prédire une efficacité de traitement de fulvestrant chez des patients atteints de cancer
DK3169815T3 (da) 2014-07-15 2021-02-15 Ontario Institute For Cancer Res Fremgangsmåder og indretninger til forudsigelse af anthracyclinbehandlingseffektivitet
GB2579856A (en) * 2018-12-18 2020-07-08 Emergex Vaccines Holding Ltd MHC Class I associated peptides for prevention and treatment of hepatitis B virus infection
WO2021205408A1 (fr) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Immunoglobulines igy ciblant le coronavirus, procédés pour les préparer, et procédés les utilisant
CN117821469B (zh) * 2023-11-22 2024-08-02 扬州大学 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (fr) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Vecteur d'adenovirus de recombinaison avien
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (fr) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Vecteur d'adenovirus de recombinaison avien
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROLLIER CHRISTINE ET AL: "Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection.", JOURNAL OF VIROLOGY, vol. 74, no. 10, May 2000 (2000-05-01), pages 4908 - 4911, XP002192933, ISSN: 0022-538X *
SAKAGUCHI M ET AL: "Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 8, 1 June 1996 (1996-06-01), pages 747 - 752, XP004069557, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2001259631A1 (en) 2001-11-26
WO2001088162A2 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
WO2001088162A3 (fr) Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
ITRM930301A1 (it) Procedimento per la preparazione di immunogeni e reagenti diagnostici, e immunogeni e reagenti diagnostici cosi' ottenibili.
EP1616876A3 (fr) Procédé d'identification, d'isolation et de production d'antigènes a un pathogène spécifique
US8241894B2 (en) Method for analyzing proteins
WO2003099999A3 (fr) Production et selection d'une banque de proteines dans de la silice
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
EP2277917A3 (fr) Cible de surface B7-H3L et famille d'anticorps reconnaissant cette cible
ATE282717T1 (de) Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
DE602004018388D1 (de) Proteinphosphorylierung bei grosszellig-anaplastischem lymphom
BR9915732A (pt) Geração de anticorpos usando-se vacinação de polinucleotìdeo em espécie de ave
ATE430198T1 (de) Antikörperkonstruktion unter verwendung einer mrl/lpr-maus
EP1405862A3 (fr) Procédé d'identification des peptides antigéniques
WO2000073430A3 (fr) Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides
EP2289907A3 (fr) Antigènes I + II de Streptococcus agalactiae
WO1999036568A3 (fr) Procede d'identification de fragments de proteine stimulant les lymphocytes t
Shin et al. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer
PH12021550470A1 (en) Improved anti-flt3 antigen binding proteins
WO1999000671A3 (fr) Procede d'identification d'antigenes de proteines cellulaires et de detection de la presence d'anticorps diriges contre des proteines cellulaires specifiques du serum
DE69829587D1 (de) Nukleinsäuremoleküle, die mit dem schwachen rhesus-d phänotyp korrelieren
WO2001085989A3 (fr) Facteurs specifiques aux filaments mycelliens extraits de candida albicans
WO2003042366A3 (fr) Nouveau gene saitohin et utilisation de celui-ci
WO2000055192A3 (fr) Molecule d'acides nucleiques, comprenant une sequence d'acides nucleiques codant pour une hemocyanine
McCormick et al. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1
WO2002000829A3 (fr) Nouveau polypeptide, proteine humaine 16.83 ftsh, et polynucleotide codant ce polypeptide
WO2000034294A3 (fr) Homologue recepteur du facteur de necrose tumorale (trh1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP